1. Home
  2. GRFS vs PTGX Comparison

GRFS vs PTGX Comparison

Compare GRFS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$7.84

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$92.20

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRFS
PTGX
Founded
1940
2006
Country
Spain
United States
Employees
25247
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.2B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
GRFS
PTGX
Price
$7.84
$92.20
Analyst Decision
Hold
Strong Buy
Analyst Count
2
12
Target Price
$10.15
$100.17
AVG Volume (30 Days)
682.6K
537.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.79%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.33
$711.26
Revenue Next Year
$6.50
N/A
P/E Ratio
$18.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.19
$39.60
52 Week High
$11.14
$100.00

Technical Indicators

Market Signals
Indicator
GRFS
PTGX
Relative Strength Index (RSI) 27.72 53.45
Support Level $7.64 $76.63
Resistance Level $9.11 $94.89
Average True Range (ATR) 0.29 4.12
MACD -0.12 0.27
Stochastic Oscillator 2.99 38.54

Price Performance

Historical Comparison
GRFS
PTGX

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Share on Social Networks: